Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

A Cross-Layer, Anomaly-Based IDS for WSN and MANET.

Amouri A, Morgera SD, Bencherif MA, Manthena R.

Sensors (Basel). 2018 Feb 22;18(2). pii: E651. doi: 10.3390/s18020651.

2.

Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study.

Poller WC, Berger A, Dreger H, Morgera S, Enke-Melzer K.

Atheroscler Suppl. 2017 Nov;30:174-179. doi: 10.1016/j.atherosclerosissup.2017.05.007. Epub 2017 Jun 1.

PMID:
29096834
3.

Reactive near field electromagnetic axonal communication channels and their role in neurodegenerative diseases.

Morgera SD.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:2307-10. doi: 10.1109/EMBC.2015.7318854.

PMID:
26736754
4.

Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study.

Slowinski T, Morgera S, Joannidis M, Henneberg T, Stocker R, Helset E, Andersson K, Wehner M, Kozik-Jaromin J, Brett S, Hasslacher J, Stover JF, Peters H, Neumayer HH, Kindgen-Milles D.

Crit Care. 2015 Sep 29;19:349. doi: 10.1186/s13054-015-1066-7.

5.

Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a).

Poller WC, Dreger H, Morgera S, Berger A, Flessenkämper I, Enke-Melzer K.

Atheroscler Suppl. 2015 May;18:187-93. doi: 10.1016/j.atherosclerosissup.2015.02.032.

PMID:
25936325
6.

Association between renal replacement therapy in critically ill patients with severe acute kidney injury and mortality.

Bagshaw SM, Uchino S, Kellum JA, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM, Ronco C, Bellomo R; Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators.

J Crit Care. 2013 Dec;28(6):1011-8. doi: 10.1016/j.jcrc.2013.08.002. Epub 2013 Sep 24.

PMID:
24075302
7.

Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk.

Kalb R, Kram R, Morgera S, Slowinski T, Kindgen-Milles D.

Ther Apher Dial. 2013 Apr;17(2):202-12. doi: 10.1111/j.1744-9987.2012.01101.x. Epub 2012 Aug 29.

PMID:
23551677
8.

Regional anticoagulation with citrate: expanding its indications.

Morgera S.

Crit Care Med. 2011 Feb;39(2):399-400. doi: 10.1097/CCM.0b013e318205c500. No abstract available.

PMID:
21248519
9.

Survival benefit with regional anticoagulation with citrate in CRRT: the end of a myth?

Morgera S.

Nephrol Dial Transplant. 2011 Jan;26(1):9-11. doi: 10.1093/ndt/gfq711. Epub 2010 Dec 8. No abstract available.

PMID:
21148029
10.

Does endothelin B receptor deficiency ameliorate the induction of peritoneal fibrosis in experimental peritoneal dialysis?

Kalk P, Rückert M, Godes M, von Websky K, Relle K, Neumayer HH, Hocher B, Morgera S.

Nephrol Dial Transplant. 2010 May;25(5):1474-8. doi: 10.1093/ndt/gfp652. Epub 2009 Nov 26.

PMID:
19945955
11.

Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study.

Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Straaten HO, Ronco C, Kellum JA.

Crit Care Med. 2009 Sep;37(9):2576-82. doi: 10.1097/CCM.0b013e3181a38241.

PMID:
19623048
12.

A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status.

Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, Peters H, Kindgen-Milles D, Neumayer HH.

Crit Care Med. 2009 Jun;37(6):2018-24. doi: 10.1097/CCM.0b013e3181a00a92.

PMID:
19384210
13.

A comparison of observed versus estimated baseline creatinine for determination of RIFLE class in patients with acute kidney injury.

Bagshaw SM, Uchino S, Cruz D, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM, Ronco C, Kellum JA; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators.

Nephrol Dial Transplant. 2009 Sep;24(9):2739-44. doi: 10.1093/ndt/gfp159. Epub 2009 Apr 6.

PMID:
19349297
14.

Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury.

Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM, Ronco C, Kellum JA; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators.

J Crit Care. 2009 Mar;24(1):129-40. doi: 10.1016/j.jcrc.2007.12.017. Epub 2008 Apr 18.

PMID:
19272549
15.

Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy.

Kleeberg L, Morgera S, Jakob C, Hocher B, Schneider M, Peters H, Rötzer S, Müller C, Kaiser M, Fleissner C, Heider U, Neumayer HH, Sezer O.

Eur J Med Res. 2009;14:47-54.

16.

The effect of three different miniaturized blood purification devices on plasma cytokine concentration in an ex vivo model of endotoxinemia.

Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Storr M, Krause B, Boyce N, Svobodova S, Li W, Bagshaw SM, Warrillow S, Langenberg C, Morgera S.

Int J Artif Organs. 2008 Aug;31(8):722-9.

PMID:
18825645
17.

Treatment of severe hypercalcemia using continuous renal replacement therapy with regional citrate anticoagulation.

Kindgen-Milles D, Kram R, Kleinekofort W, Morgera S.

ASAIO J. 2008 Jul-Aug;54(4):442-4. doi: 10.1097/MAT.0b013e31817dc3be.

PMID:
18645366
18.

The use of contrast-enhanced US in renal transplant: first results and potential clinical benefit.

Fischer T, Dieckhöfer J, Mühler M, Lembcke A, Morgera S, Budde K, Neumayer HH, Ebeling V, Thomas A, Filimonow S.

Eur Radiol. 2005 Dec;15 Suppl 5:E109-16.

PMID:
18637238
19.

Treatment of metabolic alkalosis during continuous renal replacement therapy with regional citrate anticoagulation.

Kindgen-Milles D, Amman J, Kleinekofort W, Morgera S.

Int J Artif Organs. 2008 Apr;31(4):363-6.

PMID:
18432594
20.

Long-term outcomes after acute kidney injury.

Morgera S, Schneider M, Neumayer HH.

Crit Care Med. 2008 Apr;36(4 Suppl):S193-7. doi: 10.1097/CCM.0b013e318168cae2. Review.

PMID:
18382193
21.

Citrate anticoagulation protocol for slow extended hemodialysis with the Genius dialysis system in acute renal failure.

Schneider M, Liefeldt L, Slowinski T, Peters H, Neumayer HH, Morgera S.

Int J Artif Organs. 2008 Jan;31(1):43-8.

PMID:
18286453
22.

Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.

Krämer S, Kron S, Wang-Rosenke Y, Loof T, Khadzhynov D, Morgera S, Kawachi H, Shimizu F, Martini S, Neumayer HH, Peters H.

Am J Physiol Renal Physiol. 2008 Apr;294(4):F801-11. doi: 10.1152/ajprenal.00148.2007. Epub 2008 Jan 23.

23.

High cut-off point membranes in septic acute renal failure: a systematic review.

Haase M, Bellomo R, Morgera S, Baldwin I, Boyce N.

Int J Artif Organs. 2007 Dec;30(12):1031-41. Review. Erratum in: Int J Artif Organs. 2008 Jan;31(1):88. Morger, S [corrected to Morgera, S].

PMID:
18203064
24.

N-Acetylcysteine does not artifactually lower plasma creatinine concentration.

Haase M, Haase-Fielitz A, Ratnaike S, Reade MC, Bagshaw SM, Morgera S, Dragun D, Bellomo R.

Nephrol Dial Transplant. 2008 May;23(5):1581-7. doi: 10.1093/ndt/gfm818. Epub 2008 Jan 17.

PMID:
18202091
25.

Efficacy and safety of intermittent hemodialysis using citrate as anticoagulant: a prospective study.

Schneider M, Thomas K, Liefeldt L, Kindgen-Milles D, Peters H, Neumayer HH, Morgera S.

Clin Nephrol. 2007 Nov;68(5):302-7.

PMID:
18044262
26.

Analysis of the actions of nucleus reuniens and the entorhinal cortex on EEG and evoked population behavior of the hippocampus.

Morales GJ, Ramcharan EJ, Sundararaman N, Morgera SD, Vertes RP.

Conf Proc IEEE Eng Med Biol Soc. 2007;2007:2480-4.

PMID:
18002497
27.

Sodium citrate anticoagulation during sustained low efficiency dialysis (SLED) in patients with acute renal failure and severely impaired liver function.

Morath C, Miftari N, Dikow R, Hainer C, Zeier M, Morgera S, Weigand MA, Schwenger V.

Nephrol Dial Transplant. 2008 Jan;23(1):421-2. Epub 2007 Oct 3. No abstract available.

PMID:
17913732
28.

Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes.

Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM, Ronco C, Kellum JA; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators.

Clin J Am Soc Nephrol. 2007 May;2(3):431-9. Epub 2007 Mar 21.

29.

Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial.

Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Davenport P, Morgera S, Goehl H, Storr M, Boyce N, Neumayer HH.

Am J Kidney Dis. 2007 Aug;50(2):296-304.

PMID:
17660031
30.

Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.

Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten H, Ronco C, Kellum JA.

Intensive Care Med. 2007 Sep;33(9):1563-70. Epub 2007 Jun 27.

PMID:
17594074
31.

Beta2-microglobulin removal and plasma albumin levels with high cut-off hemodialysis.

Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Morgera S, Goehl H, Storr M, Boyce N, Neumayer HH.

Int J Artif Organs. 2007 May;30(5):385-92.

PMID:
17551901
32.

Patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury.

Uchino S, Bellomo R, Kellum JA, Morimatsu H, Morgera S, Schetz MR, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-Van Straaten HM, Ronco C; Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators Writing Committee.

Int J Artif Organs. 2007 Apr;30(4):281-92.

PMID:
17520564
33.

Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study.

Birnbaum J, Spies CD, Klotz E, Hein OV, Morgera S, Schink T, Ziemer S, Grund MS, Saalmann R, Kox WJ, Lehmann C.

Ren Fail. 2007;29(3):271-7.

PMID:
17497439
34.

Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients.

Haase M, Haase-Fielitz A, Bagshaw SM, Reade MC, Morgera S, Seevenayagam S, Matalanis G, Buxton B, Doolan L, Bellomo R.

Crit Care Med. 2007 May;35(5):1324-31.

PMID:
17414730
35.

Arrival time parametric imaging: a new ultrasound technique for quantifying perfusion of kidney grafts.

Fischer T, Filimonow S, Rudolph J, Morgera S, Budde K, Slowinski T, Ebeling V, Taymoorian K, Giessing M, Thomas A.

Ultraschall Med. 2008 Aug;29(4):418-23. Epub 2007 Feb 21.

PMID:
17315111
36.

Successful pregnancies in dialysis patients including those suffering from cystinosis and familial Mediterranean fever.

Haase M, Morgera S, Bamberg C, Halle H, Martini S, Dragun D, Neumayer HH, Budde K.

J Nephrol. 2006 Sep-Oct;19(5):677-81.

PMID:
17136701
37.

[Renal transplant: color duplex ultrasound and contrast-enhanced ultrasound in the evaluation of the early postoperative phase and surgical complications].

Fischer T, Filimonow S, Mutze S, Morgera S, Thomas A.

Rofo. 2006 Dec;178(12):1202-11. Epub 2006 Nov 29. Review. German.

PMID:
17133291
38.

Improved diagnosis of early kidney allograft dysfunction by ultrasound with echo enhancer--a new method for the diagnosis of renal perfusion.

Fischer T, Filimonow S, Dieckhöfer J, Slowinski T, Mühler M, Lembcke A, Budde K, Neumayer HH, Ebeling V, Giessing M, Thomas A, Morgera S.

Nephrol Dial Transplant. 2006 Oct;21(10):2921-9. Epub 2006 Jul 5.

PMID:
16822787
39.

Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure.

Morgera S, Haase M, Kuss T, Vargas-Hein O, Zuckermann-Becker H, Melzer C, Krieg H, Wegner B, Bellomo R, Neumayer HH.

Crit Care Med. 2006 Aug;34(8):2099-104.

PMID:
16763508
40.

Renal vascular resistance in sepsis.

Langenberg C, Bellomo R, May CN, Egi M, Wan L, Morgera S.

Nephron Physiol. 2006;104(1):p1-11. Epub 2006 May 10.

PMID:
16691034
41.

[A new method for standardized diagnosis following renal transplantation. Ultrasound with contrast enhancement].

Fischer T, Ebeling V, Giessing M, Mühler M, Filimonow S, Dieckhöfer J, Lembcke A, Rudolph J, Morgera S, Budde K, Hamm B, Thomas A.

Urologe A. 2006 Jan;45(1):38-45. German.

PMID:
16328214
42.

Regional citrate anticoagulation in continuous hemodialysis--acid-base and electrolyte balance at an increased dose of dialysis.

Morgera S, Haase M, Ruckert M, Krieg H, Kastrup M, Krausch D, Vargas-Hein O, Zuckermann-Becker H, Peters H, Pohlmeier R, Neumayer HH.

Nephron Clin Pract. 2005;101(4):c211-9. Epub 2005 Sep 8.

PMID:
16155399
43.

External validation of severity scoring systems for acute renal failure using a multinational database.

Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Doig GS, Oudemans van Straaten H, Ronco C, Kellum JA; Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators.

Crit Care Med. 2005 Sep;33(9):1961-7.

PMID:
16148466
44.

Renal blood flow in sepsis.

Langenberg C, Bellomo R, May C, Wan L, Egi M, Morgera S.

Crit Care. 2005 Aug;9(4):R363-74. Epub 2005 May 24. Review.

45.

A systematic approach to managing pregnant dialysis patients--the importance of an intensified haemodiafiltration protocol.

Haase M, Morgera S, Bamberg C, Halle H, Martini S, Hocher B, Diekmann F, Dragun D, Peters H, Neumayer HH, Budde K.

Nephrol Dial Transplant. 2005 Nov;20(11):2537-42. Epub 2005 Aug 22.

PMID:
16115858
46.

Acute renal failure in critically ill patients: a multinational, multicenter study.

Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators.

JAMA. 2005 Aug 17;294(7):813-8.

PMID:
16106006
47.

Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients.

Vargas Hein O, Staegemann M, Wagner D, von Heymann C, Martin M, Morgera S, Spies C.

Ren Fail. 2005;27(4):385-92.

PMID:
16060124
48.

Protracted bleeding after hirudin anticoagulation for cardiac surgery in a patient with HIT II and chronic renal failure.

Hein OV, von Heymann C, Morgera S, Konertz W, Ziemer S, Spies C.

Artif Organs. 2005 Jun;29(6):507-10.

PMID:
15926989
49.

Glucose-mediated transforming growth factor-beta1 release in human mesothelial cells is endothelin independent.

Morgera S, Schlenstedt J, Giessing M, Deger S, Hocher B, Neumayer HH.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S216-8.

PMID:
15838283
50.

Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report.

Naka T, Jones D, Baldwin I, Fealy N, Bates S, Goehl H, Morgera S, Neumayer HH, Bellomo R.

Crit Care. 2005 Apr;9(2):R90-5. Epub 2005 Jan 21.

Supplemental Content

Loading ...
Support Center